Markets
BUSINESS NEWS
- Market News
- Earnings
- Recalls
- Recession Watch
- Tech News
- Financial Crisis
- Madoff Scandal
- BloggingStocks
- Luxist
- Money Videos
INVESTING
- Stock Quotes
- Stock Charts
- Stock Ticker
- Currencies
- Portfolio
- Stock Screener
- Broker Center
- Mutual Fund Center
- ETF Center
- Money
- 24/7 Wall St.
- Financial Glossary
PERSONAL FINANCE AT WALLETPOP
- Bargains
- Banking
- Budget
- Calculators
- College Finance
- Community
- Credit
- Deals
- Debt
- Economizer
- Food
- Home
- Fraud
- Insurance
- Interest Rates
- Loans
- Mortgages
- Real Estate
- Recalls
- Recession
- Retirement
- Saving
- Simplification
- Specials
- Taxes
SMALL BUSINESS
Ariad's 3Q loss widens slightly on costs
CAMBRIDGE, Mass. (AP) — Drug developer Ariad Pharmaceuticals Inc. said Thursday its third-quarter loss widened slightly on overall costs as it continues developing potential cancer treatments.
The company reported a loss of $20.8 million, or 21 cents per share, compared with a loss of $20 million, or 29 cents per share, a year earlier. The company had fewer shares outstanding in the same period a year ago.
Revenue rose 40 percent, to $2.2 million from $1.5 million.
Analysts polled by Thomson Financial expected a loss of 18 cents per share on revenue of about $2.6 million.
The company's lead product candidates include the cancer treatment ridaforolimus, which is being developed in a partnership with Merck&Co.
Shares of Ariad closed at $1.98 Thursday.